Paper Details

  1. Home
  2. Paper Details

Comparison of ceftibuten versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis.

Author: AubierM A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ceftibuten, administered once or twice daily, was found to be equally effective as amoxicillin/clavulanate in treating acute exacerbations of chronic bronchitis. Ceftibuten was better tolerated, with fewer gastrointestinal side effects.
Paper Details　
Original Abstract of the Article :
The efficacy and tolerability of once- or twice-daily ceftibuten (400 mg daily) were compared with three-times daily amoxicillin/clavulanate (AMX/CA, 500 mg/125 mg) in the treatment of acute exacerbations of chronic bronchitis (AECB) in an open, parallel-group 10- to 14-day study in 443 patients. Pa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000239581

データ提供：米国国立医学図書館（NLM）

Ceftibuten vs. Amoxicillin/Clavulanate: A Battle in the Desert of Respiratory Infections

The world of respiratory infections is a vast and unforgiving desert, with acute exacerbations of chronic bronchitis (AECB) being a common ailment. This study compares the efficacy and tolerability of two antibiotics, ceftibuten and amoxicillin/clavulanate, in treating AECB.

A New Path in the Desert: Ceftibuten's Potential

This study highlights the importance of finding effective and well-tolerated treatments for AECB. The researchers found that ceftibuten, a cephalosporin antibiotic, is clinically equivalent to amoxicillin/clavulanate, a commonly used antibiotic combination. Both treatments resulted in a high rate of clinical cure, with ceftibuten showing a better tolerance profile, leading to fewer gastrointestinal side effects.

Breathing Easier in the Desert: The Benefits of Ceftibuten

This study suggests that ceftibuten could be a valuable alternative to amoxicillin/clavulanate in the treatment of AECB. Its effectiveness and superior tolerability offer patients a potentially less burdensome treatment option, helping them navigate the desert of respiratory illness with greater ease.

Dr.Camel's Conclusion

This study is like finding a smoother path through the desert of respiratory infections. Ceftibuten's efficacy and tolerability make it a potentially valuable alternative for AECB patients. It's a reminder that finding the right treatment can significantly improve the journey through illness.

Date :
  1. Date Completed 1997-08-21
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

9209787

DOI: Digital Object Identifier

10.1159/000239581

Related Literature

Article Analysis
・Side Effects of ceftibuten
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.